STERIS (STE) Earnings Date & Reports

Key Takeaways

• STERIS reported adjusted earnings per share (EPS) of $2.94 for its fiscal 2027 second quarter, beating the consensus estimate of $2.68 by roughly 9.8%.
• Revenue reached $1.59 billion, ahead of the $1.56 billion consensus and up about 8.8% from the same period a year earlier.
• Life Sciences was the standout, with capital equipment revenue surging 53% and segment revenue rising nearly 18% year over year.
• Management raised full-year adjusted EPS guidance to $11.35–$11.55, up from a prior range of $11.10–$11.30.
• Applied Sterilization Technologies capital equipment revenue declined 21%, and its full-year organic growth outlook was trimmed.
• For more detail on STERIS, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover additional trade ideas and market insights by exploring Trending AI Robots.

Earnings Context and Why It Matters

STERIS plc is a global provider of infection-prevention products and services, operating across Healthcare, Life Sciences, and Applied Sterilization Technologies segments. Its quarterly results serve as a barometer for hospital procedure volumes, medical-device manufacturing activity, and biopharmaceutical demand. The fiscal 2027 second quarter, which ended September 30, 2026, follows a fiscal first quarter in which the company posted adjusted EPS of $2.59 on revenue of $1.49 billion. With analysts focused on segment-level momentum and margin durability, this report carried added weight because it reveals whether strength in capital equipment and services could support a raised full-year outlook amid ongoing tariff costs and trade-policy uncertainty.

Reported Results

STERIS reported adjusted diluted EPS of $2.94 for the fiscal 2027 second quarter, exceeding the consensus estimate of $2.68 by approximately 9.8% and rising from $2.47 in the year-ago quarter. Revenue came in at $1.59 billion, above the $1.56 billion consensus and up about 8.8% year over year.

By segment, Healthcare revenue grew 8.6% to $1.12 billion, with both service and consumables each up 10%. Life Sciences revenue increased nearly 18% to $170.6 million, driven by a 53% jump in capital equipment revenue. Offsetting this, Applied Sterilization Technologies capital equipment revenue fell 21%.

Management raised its full-year adjusted EPS guidance to $11.35–$11.55 from $11.10–$11.30, while keeping consolidated revenue growth guidance unchanged at 7–8%. The company noted that roughly $0.18 of the guidance midpoint increase reflects tariff refunds related to levies previously paid under the International Emergency Economic Powers Act.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like STERIS across the healthcare and infection-prevention landscape, the AI Screener offers a streamlined way to surface actionable candidates and monitor shifting market conditions.

Market Reaction and Investor Sentiment

STERIS released its fiscal 2027 second-quarter results after the U.S. market close on November 4, 2026, with its conference call scheduled for the following morning. As a result, the full market reaction will unfold in subsequent trading sessions. STERIS has beaten consensus EPS estimates in five of its last eight quarters, a track record that has historically supported steady investor confidence in the name. The combination of a double-digit EPS beat, better-than-expected revenue, and a raised full-year outlook is likely to frame sentiment positively heading into the earnings call, though investors will also weigh the softer Applied Sterilization Technologies results and the one-time nature of the tariff refunds embedded in the guidance increase.

Forward Outlook and Key Factors to Monitor

STERIS enters the second half of fiscal 2027 with an upgraded earnings outlook, but several factors will shape how investors assess the path ahead.

First, the quality of the guidance raise matters. About $0.18 of the midpoint increase stems from tariff refunds tied to the International Emergency Economic Powers Act, meaning the underlying operational raise is smaller than the headline figures suggest. Management also flagged gross tariff costs of roughly $15 million per quarter and ongoing trade-policy uncertainty as persistent headwinds.

Second, segment momentum bears watching. Life Sciences full-year organic growth expectations were lifted to 9–10% from 6–7%, but the segment's backlog declined to $93.4 million from $113.7 million, a signal investors should track as it reflects how quickly the capital equipment surge draws down future order coverage.

Third, Applied Sterilization Technologies remains a soft spot, with capital equipment revenue down 21% and its full-year organic growth outlook trimmed to 6–7% from 7–8%.

Finally, the company noted a proposed acquisition of Xodus Medical, with a revised full-year outlook incorporating that deal expected after closing. Progress on that transaction, along with demand trends in hospital procedures and biopharmaceutical capital spending, will be key areas of focus in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations